<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015974</url>
  </required_header>
  <id_info>
    <org_study_id>2015[992]</org_study_id>
    <nct_id>NCT03015974</nct_id>
  </id_info>
  <brief_title>Registry of IgA Nephropathy in Chinese Children</brief_title>
  <acronym>RACC</acronym>
  <official_title>Registry of IgA Nephropathy in Chinese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Hebei Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Province Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Institute of Pediatrics, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Women's and Children's Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Yunnan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tries to identify the safe and effective treatment option for IgA nephropathy in
      children. Investigators will perform prospective registration study among 25 pediatric
      nephrology medical centers in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 1200 patients diagnosed as primary IgA nephropathy with nephrotic proteinuria will
      be enrolled among 25 pediatric nephrology medical centers nationwide, according to the
      following protocol.

        1. Establishment of registration database online.

        2. Participants will be enrolled according to the inclusion criteria and exclusion
           criteria.

        3. The following data will be collected prospectively, including demographic data, clinical
           symptoms, physical examination, laboratory examination, renal pathology, treatment
           protocol and follow-up.

        4. SPSS software (version 14.0; SPSS, Inc., Chicago, IL, USA) will be used for statistical
           analysis. P value less than 0.05 will be considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Improvement of proteinuria</measure>
    <time_frame>Two years</time_frame>
    <description>Complete remission is defined as 24-hour urine protein&lt;150mg or UPC&lt;0.3 g/g with normal kidney function. Partial remission is defined as urine protein decreased by more than 50% with normal renal function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>Two years</time_frame>
    <description>Renal dysfunction is defined as eGFR declined by more than 50%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypertension</measure>
    <time_frame>Two years</time_frame>
    <description>Hypertension is defined as blood pressure higher than age-specific average level. Use of antihypertensive drugs will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End stage renal disease(ESRD)</measure>
    <time_frame>Two years</time_frame>
    <description>ESRD is defined as eGFR&lt;15ml/min/1.73m2, initiation of long-term dialysis or kidney transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Two years</time_frame>
    <description>Death of participants will be recorded.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>IgA Nephropathy</condition>
  <condition>Proteinuria in Nephrotic Range</condition>
  <condition>Immunosuppressive Treatment</condition>
  <arm_group>
    <arm_group_label>corticosteroid</arm_group_label>
    <description>pediatric IgA nephropathy treated with only corticosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>corticosteroid and cyclophosphamide</arm_group_label>
    <description>pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>corticosteroid and mycophenolate mofetil</arm_group_label>
    <description>pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <arm_group_label>corticosteroid</arm_group_label>
    <arm_group_label>corticosteroid and cyclophosphamide</arm_group_label>
    <arm_group_label>corticosteroid and mycophenolate mofetil</arm_group_label>
    <other_name>Steroid</other_name>
    <other_name>Prednisone</other_name>
    <other_name>Methylprednisone</other_name>
    <other_name>Prednisolone</other_name>
    <other_name>Deflazacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>corticosteroid and cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>corticosteroid and mycophenolate mofetil</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole</intervention_name>
    <arm_group_label>corticosteroid</arm_group_label>
    <arm_group_label>corticosteroid and cyclophosphamide</arm_group_label>
    <arm_group_label>corticosteroid and mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE Inhibitor or Angiotensin receptor antagonist</intervention_name>
    <arm_group_label>corticosteroid</arm_group_label>
    <arm_group_label>corticosteroid and cyclophosphamide</arm_group_label>
    <arm_group_label>corticosteroid and mycophenolate mofetil</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The urine, serum and DNA of participants are expected to be collected and preserved.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 1200 patients diagnosed as primary IgA nephropathy with nephrotic proteinuria
        will be enrolled among 25 pediatric nephrology medical centers nationwide.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        In-patients will be enrolled with the following criteria.

        Inclusion Criteria:

          -  Clinical diagnosis of primary IgA nephropathy.

          -  Presenting with nephrotic proteinuria, defined as 24-hour urinary protein&gt;50mg/kg, or
             UPC&gt;2.0 mg/mg.

          -  Informed consent must be signed.

        Exclusion Criteria:

          -  Diagnosed as secondary renal diseases, including lupus nephritis, purpura nephritis,
             hepatitis B virus associated nephritis, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Ding, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuhui Zhong, Dr.</last_name>
    <phone>8613683556856</phone>
    <email>xuhui7876@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Ding, Prof.</last_name>
    <phone>861083573238</phone>
    <email>djnc_5855@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhui Zhong, Dr.</last_name>
      <phone>8613683556856</phone>
      <email>xuhui7876@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Jie Ding</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

